Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Actinium Pharmaceuticals Provides Third Quarter 2026 Corporate Update Highlighting ATNM-400 and Other Business Progress

      Actinium Pharmaceuticals Logo

      News provided by

      Actinium Pharmaceuticals, Inc.

      Nov 17, 2026, 07:00 ET

      Share this article

      Share this article


      • Announced HER3 as the target of ATNM-400 and presented initial data from the first-in- human HERACT-PRO-1 Phase 1/2a study in metastatic castration-resistant prostate cancer (mCRPC) at EANM 2026
      • Initiated RADIANZ pan-tumor imaging study to inform ATNM-400 development across multiple solid tumors beyond prostate cancer
      • Formed Scientific Advisory Board and strengthened leadership team to support strategic execution, business development and continued pipeline advancement
      • KOL webinar on ATNM-400 on December 1, 2026, at 8:00 a.m. ET with Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center

      NEW YORK, Nov. 17, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies with the potential to transform cancer treatment, today provided a third quarter 2026 corporate update highlighting recent clinical progress with ATNM-400, initiation of its RADIANZ pan-tumor imaging study, and advancements across its broader pipeline. With ATNM-400 now in clinical development for prostate cancer and multiple clinical and scientific milestones anticipated across its portfolio in 2027, Actinium is entering an important period of pipeline advancement.

      "With ATNM-400 now in the clinic, we are advancing a differentiated HER3-targeted approach to alpha radiotherapy with the potential to address significant unmet needs in prostate cancer beyond PSMA," said Sandesh Seth, Actinium's Chairman and Chief Executive Officer. "Our encouraging initial clinical findings support continued dose escalation in mCRPC, while RADIANZ represents an important next step in evaluating HER3 targeting across multiple large solid tumor indications. Looking ahead, 2027 is shaping up to be an important year for Actinium, with anticipated clinical data and development milestones across ATNM-400, Actimab-A and Iomab-ACT. Together with our newly formed Scientific Advisory Board and strengthened leadership team, we believe we are well positioned to execute on these priorities and build value across our differentiated targeted radiotherapy pipeline."

      Third Quarter 2026 and Recent Highlights

      ATNM-400: First-in-Class HER3-Targeted Alpha Radiotherapy

      • Target disclosed and encouraging first-in-human data presented at EANM 2026. Actinium announced HER3, an antigen distinct from PSMA and implicated in treatment resistance, as the target of ATNM-400 and presented initial results from the ongoing HERACT-PRO-1 Phase 1/2a study in mCRPC. The first cohort cleared the 1.0 µCi/kg dose level with no dose-limiting toxicities, and imaging showed tumor uptake retained through Day 7. Dose escalation has advanced to 1.5 µCi/kg and is ongoing. The study was also featured at ESMO 2026.
      • RADIANZ pan-tumor imaging study enrolling to inform development beyond prostate cancer. The first patient was dosed in RADIANZ, a HER3 PET imaging study in advanced lung, breast, colorectal, pancreatic and ovarian cancers designed to inform ATNM-400 development beyond prostate cancer.
      • Preclinical data reinforce ATNM-400's pan-tumor potential. New data presented at EANM demonstrated antitumor activity across non-small cell lung cancer (NSCLC), colorectal and ovarian cancer models, supporting the potential of ATNM-400 as a monotherapy and in combination with established treatments. Additional preclinical findings highlighting activity across breast cancer models will be presented at SABCS 2026.

      Hematology Programs

      • Four abstracts accepted for presentation at ASH 2026: Presentations will highlight long-term safety findings for Actimab-A plus CLAG-M in relapsed or refractory AML, as well as Iomab-ACT's potential as a targeted conditioning agent for CAR T-cell and gene therapies.

      Corporate

      • Formed Scientific Advisory Board of leading experts in prostate cancer, hematologic malignancies, radiochemistry and nuclear medicine: Karim Fizazi, MD, PhD (Centre Oscar Lambret and Paris-Saclay University); Sergio A. Giralt, MD (Memorial Sloan Kettering Cancer Center); Jason S. Lewis, PhD (Memorial Sloan Kettering Cancer Center); Michael J. Morris, MD (Memorial Sloan Kettering Cancer Center); and Neeta Pandit-Taskar, MD, MBA (University of Pittsburgh Medical Center).
      • Strengthened leadership team with key appointments. Appointed Matt David, M.D., as Chief Financial Officer, bringing more than 20 years of public company finance, capital markets and investment banking experience, most recently at CorMedix, and Sean Maenpaa as Senior Vice President, Business Development, a radiopharmaceutical business development veteran from Bayer, Clovis Oncology and Telix Pharmaceuticals.
      • Financial position: Cash and cash equivalents of $28.7 million as of September 30, 2026 are expected to fund operations through 2027.

      Upcoming Events

      • December 1 – KOL Webinar on ATNM-400: Actinium will host a webinar at 8:00 a.m. ET featuring Michael J. Morris, MD, Prostate Cancer Section Head at Memorial Sloan Kettering Cancer Center. The discussion will focus on unmet needs in mCRPC, the potential for HER3-targeted alpha radiotherapy beyond PSMA, and management's review of previously reported HERACT-PRO-1 clinical findings and the RADIANZ imaging study.   Register here.
      • December 8-11 – SABCS 2026: Actinium will present preclinical data demonstrating ATNM-400's activity across therapy-resistant breast cancer models, further supporting its potential across multiple solid tumor indications. The poster presentation is scheduled for December 9, 2026.
      • December 12-15 – ASH 2026: Actinium will present clinical findings from its Actimab-A and Iomab-ACT programs, highlighting continued development in AML, CAR T-cell conditioning and gene therapy conditioning.

      Looking ahead, Actinium expects a steady cadence of clinical data, scientific presentations and development milestones throughout 2027 as it advances ATNM-400 in prostate cancer and evaluates its broader solid tumor potential, alongside continued progress across its hematology pipeline. In addition, Actinium continues to establish in-house manufacturing capabilities to support its clinical programs and expects to be operational by around year-end.

      About Actinium Pharmaceuticals, Inc.

      Actinium is a pioneer in targeted radiotherapies designed to improve outcomes for patients with cancer. The Company employs a biology-driven approach to develop differentiated radiopharmaceuticals for solid tumors and hematologic malignancies. Its pipeline spans three areas: (1) solid tumor therapeutics including ATNM-400 and Actimab-A with pan-tumor potential; (2) Actimab-A as a therapeutic backbone for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in collaboration with the National Cancer Institute (NCI); and (3) targeted conditioning agents including Iomab-B for bone marrow transplant and Iomab-ACT for cell and gene therapy conditioning. Actinium also holds approximately 250 patents and patent applications, including intellectual property related to cyclotron-based production of Actinium-225. For more information, please visit www.actiniumpharma.com.

      About ATNM-400

      ATNM-400 is an investigational antibody radioconjugate that pairs the HER3-targeting monoclonal antibody barecetamab with the alpha-emitting isotope Actinium-225. Its antibody-based design combines antigen-specific targeting with the potential for sustained tumor localization, supporting prolonged delivery of high-energy alpha radiation. Tumor uptake and retention observed through Day 7 with the ⁸⁹Zr-labeled imaging counterpart support this development rationale alongside the approximately 10-day half-life of ²²⁵Ac. The theranostic approach enables noninvasive visualization of antibody distribution to inform therapeutic development.  The program is being evaluated in a first-in-human dose-escalation Phase 1/2a study of ATNM-400 in mCRPC, HERACT-PRO-1, which utlizes Zirconium-89-labeled barecetamab PET imaging to assess tumor targeting, biodistribution and dosimetry. Actinium is also conducting an imaging study, RADIANZ (Radiolabeled Antibody Distribution In Advanced Neoplasms with Zirconium-89) using PET to guide the pan-tumor development of ATNM-400 in various solid tumors outside of prostate cancer.

      ATNM-400 is differentiated from PSMA-targeted radiotherapies by its focus on HER3, an antigen implicated in tumor survival and treatment resistance. PSMA-directed approaches include Novartis' Pluvicto and a broad pipeline of investigational therapies, including Telix Pharmaceuticals' TLX591-Tx, Clarity Pharmaceuticals' ⁶⁷Cu-SAR-bisPSMA, Convergent Therapeutics' CONV01-α, AstraZeneca's AZD2265 (formerly FPI-2265), Curium's lutetium-177 zadavotide guraxetan (¹⁷⁷Lu-PSMA-I&T), ARTBIO's AB001 and AdvanCell's ADVC001. These programs span small-molecule and antibody-based therapies using beta- or alpha-emitting isotopes. ATNM-400 combines HER3 targeting with an Actinium-225 antibody radioconjugate, offering a distinct biological approach with the potential to expand radiotherapy across the broad mCRPC population, including patients with PSMA-low or PSMA-negative disease and those who do not respond to or progress following PSMA-directed treatment. Its HER3-directed mechanism also supports investigation beyond prostate cancer in other HER3-expressing solid tumors.

      About HER3

      HER3, also known as ERBB3, belongs to the epidermal growth factor receptor family and participates in signaling pathways that promote tumor growth, survival and treatment resistance. HER3-directed antibody-drug conjugates (ADCs) in clinical development include BioNTech and MediLink's BNT326/YL202; Bristol Myers Squibb and SystImmune's EGFR × HER3 bispecific ADC, izalontamab brengitecan (iza-bren); and Daiichi Sankyo and Merck's patritumab deruxtecan (HER3-DXd). These programs highlight clinical development interest in HER3 as an oncology target. ATNM-400 takes a different payload approach, delivering alpha radiation rather than a conventional cytotoxic drug. Preclinical activity in prostate, non-small cell lung, breast, colorectal and ovarian cancer models supports investigating ATNM-400 as a potential pan-cancer radiotherapy, both as monotherapy and in rational combinations.

      Forward-Looking Statements

      This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995 regarding future events or future financial performance of the Company, which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from anticipated or estimated future results, including risks and uncertainties associated with the conduct, timing and results of the ongoing first-in-human HERACT-PRO-1 Phase 1/2a study of ATNM-400 and the RADIANZ imaging study, including the possibility that preliminary results may differ from final results and that preclinical results may not be predictive of clinical outcomes; the sufficiency of the Company's cash resources to fund its planned operations; the potential of product candidates; clinical trials; actions by the FDA and other governmental agencies; regulatory clearances; market demand for and acceptance of the Company's products and services; performance of clinical research organizations; and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, each as amended and supplemented from time to time.

      Investors Contact:
      Peter (PJ) Kelleher
      LifeSci Advisors
      [email protected]
      (617) 430-7579

      SOURCE Actinium Pharmaceuticals, Inc.

      Modal title

      Also from this source

      Actinium Pharmaceuticals to Host KOL Webinar on ATNM-400, a First-in-Class HER3-Targeted Alpha Radiotherapy

      Actinium Pharmaceuticals to Host KOL Webinar on ATNM-400, a First-in-Class HER3-Targeted Alpha Radiotherapy

      Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today...

      Actinium Pharmaceuticals Announces Enrollment in the RADIANZ Imaging Clinical Trial Intended to Demonstrate the Pan-Cancer Potential of ATNM-400, A First-in-Class HER3-Targeting Radiotherapy

      Actinium Pharmaceuticals Announces Enrollment in the RADIANZ Imaging Clinical Trial Intended to Demonstrate the Pan-Cancer Potential of ATNM-400, A First-in-Class HER3-Targeting Radiotherapy

      Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the...

      More Releases From This Source

      Explore

      Pharmaceuticals

      Pharmaceuticals

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Clinical Trials & Medical Discoveries

      Clinical Trials & Medical Discoveries

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.